Trastuzumab

Generic Name: Trastuzumab

Brand Names: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue

Drug Type: Biotech

Chemical Formula: -

CAS Number: 180288-69-1

Unique Ingredient Identifier: P188ANX8CK

Background: Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...

Indication: For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...

Associated Conditions: Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer

Associated Therapies: -

Clinical Trials

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: PRO Onc Assay and Treatment
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2010-01-13

Last Posted Date: 2016-01-29

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 283

Registration Number: NCT01048099

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸
Florida Cancer Specialists, St. Petersburg, Florida, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 3 locations

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Trastuzumab
Drug: Fluorouracil
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2009-12-31

Last Posted Date: 2014-11-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 584

Registration Number: NCT01041404

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2009-12-04

Last Posted Date: 2018-08-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 452

Registration Number: NCT01026142

Locations: 🇧🇪
UZ Brussel, Brussel, Belgium
🇭🇰
Queen Mary Hospital; Surgery, Hong Kong, Hong Kong
🇷🇺
Semashko Central Clinical Hospital; Dept of Chemotherapy, Moscow, Russian Federation

and more 187 locations

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Trastuzumab
Drug: Neratinib
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2009-11-05

Last Posted Date: 2021-10-25

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 141

Registration Number: NCT01008150

Locations: 🇺🇸
Edward Cancer Center Plainfield, Plainfield, Illinois, United States
🇺🇸
University Hospital and Medical Center - SUNY Stony Brook, Stony Brook, New York, United States
🇺🇸
West Virginia University Hospitals Inc., Morgantown, West Virginia, United States

and more 38 locations

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer
HER2/Neu Over-expressing Locally Advanced Breast Cancer

Interventions: Drug: Placebo
Drug: everolimus
Drug: vinorelbine
Drug: trastuzumab

First Posted Date: 2009-11-04

Last Posted Date: 2017-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 569

Registration Number: NCT01007942

Locations: 🇺🇸
University of Arizona / Cancer Center AZ Onc Assoc, Tucson, Arizona, United States
🇺🇸
Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States
🇺🇸
Memorial Hospital Memorial Cancer Institute, Hollywood, Florida, United States

and more 41 locations

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Lapatinib
Drug: Letrozole
Drug: Trastuzumab

First Posted Date: 2009-10-22

Last Posted Date: 2023-06-18

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 128

Registration Number: NCT00999804

Locations: 🇺🇸
Baylor College of Medicine Lester and Sue Smith Breast Center, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States

and more 5 locations

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Pertuzumab
Drug: TCH
Drug: Trastuzumab
Drug: FEC
Drug: Docetaxel

First Posted Date: 2009-09-15

Last Posted Date: 2017-02-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 225

Registration Number: NCT00976989

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Pictilisib
Drug: Letrozole
Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2009-08-18

Last Posted Date: 2016-12-15

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 71

Registration Number: NCT00960960

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Trastuzumab
Drug: BIBW 2992

First Posted Date: 2009-08-03

Last Posted Date: 2015-07-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT00950742

Locations: 🇬🇧
1200.68.44001 Boehringer Ingelheim Investigational Site, Brighton, United Kingdom
🇬🇧
1200.68.44003 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom
🇬🇧
1200.68.44005 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom

and more 2 locations

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: nab-paclitaxel
Drug: trastuzumab
Drug: Doxorubicin
Drug: cyclophosphamide
Biological: Growth Factor Support
Procedure: Surgery

First Posted Date: 2009-07-22

Last Posted Date: 2018-04-23

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 32

Registration Number: NCT00944047

Locations: 🇺🇸
University of Kansas Medical Center Cancer Center, Kansas City, Kansas, United States
🇺🇸
Hays Medical Center, Hays, Kansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy